Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.

Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2007 Apr;56(4):459-68. Epub 2006 Aug 26.


An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.

Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A.

Ann Oncol. 2010 Feb;21(2):275-82. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24.


In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.

Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T.

Int J Cancer. 2002 Jul 1;100(1):101-10.


Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.


High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.

Mol Immunol. 2006 Mar;43(8):1183-93. Epub 2005 Aug 15.


Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6.


Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.


High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2010 Dec;203(6):582.e1-7. doi: 10.1016/j.ajog.2010.07.041. Epub 2010 Sep 25.


Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.

Kurtz JE, Dufour P.

Expert Opin Biol Ther. 2010 Jun;10(6):951-8. doi: 10.1517/14712598.2010.482098. Review.


Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ.

Br J Cancer. 2005 Jan 31;92(2):342-9.


Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R, Kufer P, Baeuerle PA, Schlereth B.

Cancer Res. 2008 Jan 1;68(1):143-51. doi: 10.1158/0008-5472.CAN-07-2182.


Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.

Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T.

Cancer Res. 1999 Nov 15;59(22):5778-84.


Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.


Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.

Cancer Res. 2010 Dec 15;70(24):10243-54. doi: 10.1158/0008-5472.CAN-10-1996. Erratum in: Cancer Res. 2011 Feb 15;71(4):1507.


Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.


Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.

Kirman I, Whelan RL.

Curr Opin Mol Ther. 2007 Apr;9(2):190-6.


Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.

Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, Wilding JL, Mortensen NJ, Bodmer WF.

Br J Cancer. 2009 Nov 17;101(10):1758-68. doi: 10.1038/sj.bjc.6605355.


Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.

Clin Cancer Res. 2006 May 1;12(9):2879-87.


A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.

Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E.

Eur J Cancer. 2006 Oct;42(15):2530-8. Epub 2006 Aug 23.


Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.

Amann M, Friedrich M, Lutterbuese P, Vieser E, Lorenczewski G, Petersen L, Brischwein K, Kufer P, Kischel R, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2009 Jan;58(1):95-109. doi: 10.1007/s00262-008-0529-y. Epub 2008 Jul 2.


Supplemental Content

Support Center